Guanhao Biotech Co.,Ltd. (SHE:300238)

Market Cap	3.18B -4.8%
Revenue (ttm)	386.40M +1.5%
Net Income	19.64M -29.6%
EPS	0.07 -31.6%
Shares Out	265.16M
PE Ratio	166.23
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,679,600
Open	12.18
Previous Close	12.00
Day's Range	11.64 - 12.18
52-Week Range	11.67 - 19.98
Beta	0.29
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About Guanhao Biotech

Guanhao Biotech Co.,Ltd. develops, manufactures, and sells regenerative medicines and life sciences products in China. It offers NormalGEN and GrandNeuro, both a dura repair patch; ThormalGEN, a surgical patch; DermalGEN, a wound dressing product; IREAL breast patch; and Youvision corneal graft, as well as license in intraocular lenses. The company also provides Biological dura, a spinal patch; Type B dura, a spinal patch; Sterile Bio Wound Membrane; Ario Mesh; Thoracic Surgery Repair Diaphragm; and Cympic Benvimod Cream for psoriasis. In addit...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 535
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300238

Financial Performance

In 2025, Guanhao Biotech's revenue was 387.75 million, an increase of 2.72% compared to the previous year's 377.48 million. Earnings were 24.35 million, a decrease of -11.20%.